Two JAMA Pediatrics modeling studies estimate that ending universal newborn hepatitis B vaccination could lead to avoidable infections and millions more in healthcare costs.
A decision to delay hepatitis B vaccination for newborns may sound small on paper, but new U.S. research suggests the health and budget consequences could quickly add up.
Two studies published Monday in JAMA Pediatrics estimate that moving away from universal hepatitis B vaccination for newborns—an approach tied to recent federal guidance changes—could translate into tens to hundreds of preventable infections and millions in additional healthcare spending.. The analyses are modeling studies. using simulations rather than tracking patients over time. but they aim to quantify outcomes under different policy scenarios.
The policy pivot traces back to last December. when the Centers for Disease Control and Prevention dropped long-standing guidance issued in 1991 that recommended three hepatitis B vaccine doses for all newborns. including a first dose within 24 hours of birth.. CDC said the shift reflected a recommendation from the Advisory Committee on Immunization Practices. which advised replacing universal newborn vaccination with a targeted strategy: screen pregnant women and vaccinate at birth only infants born to mothers who test positive.
The framing change sparked immediate debate in medical circles.. Supporters of the new approach argue that most babies born to mothers who are not infected face extremely low risk during early life. especially the first month. and therefore do not need routine vaccination at birth.. Critics counter that the vaccine’s longstanding recommendation is built on an evidence base for both safety and effectiveness—and that parents and clinicians deserve clarity. not a more individualized decision framework.
Misryoum readers should understand why the shift matters: hepatitis B doesn’t just represent a short-term illness.. It can become chronic, increasing lifetime risk of severe liver disease, liver cancer, and premature death.. In infants, the virus is particularly dangerous.. The disease burden is not evenly distributed by age—about 90% of infected babies develop chronic infection compared with roughly 5% of adults.. Infection at birth also carries a steep risk of premature death.
How CDC’s newborn hepatitis B change reshapes risk
A key question behind the CDC’s decision is whether screening can reliably substitute for universal vaccination at birth.. Screening pregnant women can reduce the chance that newborns are exposed, but it’s not a perfect safety net.. Misryoum notes that screening gaps exist in the real world; a 2023 report from March of Dimes found hundreds of thousands of pregnant women were not screened for hepatitis B.
Even when screening happens, there is still a narrow window where exposure can occur—during birth and then within households.. Modeling studies attempt to capture those time-sensitive transmission routes. which is why they focus on delaying the initial dose. not only on whether infants receive it eventually.. The research also factors in maternal infection rates, screening patterns, and how risk can move from caregiver to child.
What the JAMA Pediatrics models estimate if shots are delayed
One of the new studies modeled outcomes for more than 3.6 million U.S.. births, approximating births in 2024.. Researchers simulated what would happen under different delay scenarios—specifically. postponing the first hepatitis B vaccine dose to 2 months or to 12 months.. The analysis concluded that delaying vaccination leads to more infections. more deaths. and higher costs compared with administering the first dose at birth.
In the 2-month delay scenario. even assuming universal coverage at that point. the model estimated 90 additional acute infections. 76 additional chronic infections. 29 additional deaths. and $16.4 million in added healthcare costs.. Under a 12-month delay, the model estimated 190 additional infections and 50 deaths, along with nearly $30 million in extra healthcare spending.
The second study compared universal vaccination with a targeted strategy—vaccinating only higher-risk infants. such as those from unscreened or hepatitis B–positive mothers.. In that simulation, if 80% of higher-risk infants were vaccinated, the model still estimated 69 additional infections.. If coverage among higher-risk infants dropped to 10%, the study estimated a much larger increase—rising to 628 additional cases.
Why the “targeted” approach may be harder than it sounds
Both modeling efforts point to a practical reality that often gets missed in policy discussions: targeted vaccination depends on the reliability of systems across the entire pregnancy-to-newborn pipeline.. That includes testing completeness. timely communication of results. clinician follow-through. and whether families—who may be navigating appointment delays or access barriers—receive the correct care at the right moment.
Misryoum also flags the role of implementation.. Vaccine recommendations at the federal level are not legally binding, and states set their own rules for immunization schedules.. In practice. vaccines may be required mainly for attendance at public school or daycare. rather than being enforced uniformly at the earliest newborn stage.. The differences between federal guidance. state policy. and real-world scheduling can produce exactly the sort of “coverage drop” that models use to estimate risk.
The bigger debate: safety concerns versus preventable disease
The hepatitis B vaccine conversation is also shaped by questions of side effects and how risks are communicated.. Misryoum acknowledges that vaccine package inserts for the infant vaccines commonly used in the U.S.. report side effects such as nausea, vomiting, and upper respiratory infections.. Post-market surveillance has documented reports of a wider range of conditions, though the frequency and causal relationship remain uncertain.
Supporters of universal vaccination emphasize that the consequences of missing early protection are far more severe for infants.. Opponents of the universal-first approach argue that individualized decision-making should replace automatic recommendations once screening is available and risks for the majority appear low.. Misryoum’s reading of the new evidence is that. even if risk for many infants is low. the cost of failure—missed screenings or delayed doses—can be substantial when scaled across millions of births.
What comes next for CDC policy and state implementation
The new studies do not settle the clinical argument by themselves. partly because they are simulations rather than direct. long-term observation.. Still. they offer a measurable way to evaluate tradeoffs: targeted strategies may reduce vaccination for some families. but delays and gaps can create a larger public health burden.
For now. the debate will likely continue across hospitals. pediatric groups. and state immunization programs—especially because federal guidance shifts can take time to translate into consistent practice on the ground.. Misryoum expects the next chapter to hinge on outcomes tracking: how frequently newborn doses are delayed. how often screening is missed. and whether targeted vaccination achieves the coverage levels assumed in favorable scenarios.